Shares in the Netherlands-incorporated generics drugmaker Mylan (Nasdaq: MYL) have suffered a near-10% hit in pre-market trading, following a disappointing financial results statement covering the final three months of 2018.
Total revenues were $3 billion, down 5% compared to the prior year period, with total revenues for 2018 coming in at $11 billion, down 4%.
Following Generally Accepted Accounting Principles (GAAP), the earnings per share (EPS) figure was $0.10, down 78%. For the full year, the EPS figure was $0.68, down 47%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze